Osteoporosis is the most common metabolic bone disease, and is characterized by compromised bone strength which predisposes individuals to an increased risk of fracture. Bone strength itself is not directly measurable, but can be inferred from bone mass and quality, with bone mass being most commonly approximated by assessing bone mineral density (BMD). A person with a BMD measurement that falls within one standard deviation (SD) of the healthy reference (30-year-old male or female) is considered to have healthy bone mass and structure (T-score >-1).
Pulmonary arterial hypertension is one of a group of rare and life-threatening diseases collectively known as pulmonary hypertension (PH). Each PH subgroup shares similar pathophysiology, clinical presentation, and therapeutic approaches.
Diabetes mellitus is a group of chronic endocrine disorders characterized by hyperglycemia due to insufficient levels or action of insulin, a hormone responsible for regulating blood sugar. Symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes, and fatigue. In the long term, the disease can also cause disabling and lifethreatening complications such as cardiovascular disease (CVD), nerve damage (neuropathy, which along with peripheral vascular disease can lead to amputations), kidney damage (nephropathy), and eye disease (leading to retinopathy, loss of vision, and potentially blindness). If untreated, life-threatening conditions can develop, including diabetic ketoacidosis (DKA), particularly in type 1 diabetes, and the hyperosmolar hyperglycemic state in type 2 diabetes
Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.
Age-related macular degeneration (AMD) is the progressive degradation of the part of the eye responsible for visual acuity, causing a loss of central vision. AMD is the leading cause of blindness in individuals who are over 65 years old. As the chances of experiencing any form of AMD increase with age, treatment of this disease is becoming even more important as life expectancies continue to rise in most regions.
Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death.
Approved drugs in the ADHF – preserved ejection fraction (acute HFpEF) space target natriuretic peptide receptors. These drugs are administered via the intravenous route.
This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Cold agglutinin disease (CAD) is a clonal B-cell lymphoproliferative disorder and a rare subgroup of autoimmune hemolytic anemia (AIHA). CAD accounts for 15–25% of AIHA and affects mainly middle aged or older individuals. The disease is characterized by the production of autoantibodies by bone marrow-derived clonal B cells which attach to erythrocytes when exposed to cold temperatures (0–4°C), causing agglutination and eventual immune-mediated hemolysis.
This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Duchenne Muscular Dystrophy (DMD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, a 10-year disease prevalence forecast, probability of success, recent events and analyst opinion, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!